COVID-19 seroprevalence in Pakistan: a cross-sectional study
- PMID: 35387815
- PMCID: PMC8987211
- DOI: 10.1136/bmjopen-2021-055381
COVID-19 seroprevalence in Pakistan: a cross-sectional study
Abstract
Objectives: This study adapted WHO's 'Unity Study' protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection.
Design: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH).
Participants: All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar.
Primary and secondary outcome measures: Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints: -Primary indicators: Seroprevalence (population and age specific).Secondary indicators: Population groups most at risk for SARS-CoV-2-infection.
Results: Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0-9 years) to 10.1% (40-59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection.
Conclusions: This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19.
Keywords: COVID-19; epidemiology; public health.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
References
-
- World Health Organization . WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020, 2020. Available: https://www.who.int/director-general/speeches/detail/who-director-genera... [Accessed 22 December 2020].
-
- Government of Pakistan . COVID-19 Dashboard 2020. Available: http://covid.gov.pk/stats/pakistan?locale=en [Accessed 22 December 2020].
-
- World Health Organization . Coronavirus disease (COVID-19) technical guidance: the unity studies: early investigation protocols 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica... [Accessed 22 December 2020].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous